RVNC - Earnings call transcript Q3 2019 | Revance Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Revance Therapeutics Third Quarter 2019 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, November 4, 2019.

I would like to turn the conference call over to Jeanie Herbert, Senior Director of Investor Relations and Corporate Communications for Revance. Ma'am, please go ahead.

Jeanie Herbert

Thank you, Towanda.

call Foley; is Schilke; Chief Officer, today's Executive and Chief on Dr. Mark Officer, Financial us from President Revance Chief Operating Joining Officer, Toby Aesthetics and Therapeutics, of Joshi; Commercial, Abhay Dustin Head Sjuts. and

XXXX. financial released the September Revance today, results Earlier quarter for ended XX,

have future release you at If section to Investor releases, like please not would distribution company's of this to which Relations found added go www.revance.com. be the received can Revance's list simply news you or to to be website, receive the

this XXXX guidance. forward-looking product on inherently the and to development forward-looking During and planned management including statements, expectations plans; product involve current make significant company's our risks launch and potential conference will These financial statements call, candidates operations; are statements related and technologies. uncertainties. and anticipated candidates, of The based Revance's business strategies and precommercial results clinical and

and results Factors be entitled, such statements these actual materially in could section describes November events anticipated XXXX, the different these Our and those of as filed ended timing XX, the Factors, from results in to the on result company could cause XX-Q in quarter risks September statements the quarterly differ X, forward-looking from of a that for SEC the XXXX. include on with as Form our factors report Risk uncertainties.

new no of and Revance result to cautions forward-looking you its not future forward-looking as expectations. undue duty changes or in a undertakes obligation reliance to statements place any events any statements on or update information,

call With that, Mark now over Foley. to the turn I'll Mark?

Mark Foley

third afternoon thank quarter call. conference joining Good for and our Thank Jeanie. everyone you, XXXX you

this evolution. exciting the I'm understanding the thrilled with I time Revance's a potential, CEO how in say role be for to all healthcare to the having into company's is and want Directors opportunities today. stepping strategy I years. is of in role deep assume reason the I the that into very at operating of Part Board of an best Revance one stepped two more of back than of the role on served First, that

recently, Based I team already and therapeutic and in on novel based unlocking significant the commercialize neuromodulator have the at CEO aesthetic that most ZELTIQ successfully in Revance the my President to I place. ability Chairman, term as confidence were high in served extensive longer our our value space. healthcare market Aesthetics while is experience on in

we're We are value. verge of as entering data significant significantly Revance's Revance that exciting milestones to several on very have the of times readouts ability and the enhance

submit of validation the license in lead for in including market. This in our to of launch approval for initiate for by to DAXI, a plan or product the lines we commercial Biologics first value of number DAXI end the the its anticipated glabellar the XXXX, treatment application DAXI of long-acting of our important achievements and BLA First, proposition for November. injection, and DaxibotulinumtoxinA will filing

dystonia trials. will Additionally, we phase for dosing use valuable by phase our in upper with results expect important data and for II of readouts phase both X DAXI fasciitis information provide the launch that cervical line plantar our therapeutics in top informing aesthetic

clinical make and represents clinical The and upon our reasons delivered leading effect results about attributes first innovation than of DAXI we aesthetics In DAXI in in therapeutics disruptive XXXX rates only the duration a treatments One is unprecedented. and XX and will of response across I'm neuromodulator that long unmatched the than excited consistent, approval. more Revance years. are trials that DAXI force in exceptional true more market the think

and to is nearing DAXI for the submit it completion package BLA we in November. Our FDA to plan

commercialization a patients year efforts In as per correction of few natural of year support all Assuming DAXI approval long. expect in provide treatments the to line -looking second we XXXX, lasting, our require with half frown were is two study prestigious now Academy making plastic excellent SAKURA of be Dermatology Journal progress in reconstructive the of to and the online fronts. peer-reviewed JAAD. soon published medical and or the is Journal in on American surgery many The would

track Our opinion They organization new the to at new have SAKURA are Dermatologic Commercial, American patients meeting shared on the of annual quality an with DAXI and or for a in From Society is I'm treatment and out effective Chicago. hires company. of people continues the and our with that pleased analysis whether able types commercial data experience appropriate, of leaders to support several Surgery we neuromodulator podium October three Sjuts pull also segmentation key treatment. option and Head been another our to Dustin key was data that launch predictable to fill of they perspective, to with from all management the switching

with half practice. pattern market. US billion-dollar aesthetics additional to healthcare information and in fully We neuromodulator in of we're We first are the launch provide glabellar for now have DAXI want protocols headlines which the enrolled DAXI Both in can market the the successful these and the infrastructure of together crow's exploratory XXXX. experience readouts integrate believe trials of four of majority facial ask first lines represent completing used further should have differentiated neuromodulator. and dosing the trials performance and premium To lines feet, now place in facial professionals into to and the in their they for explore of injection

trial in to dystonia, larger value. provide a of robust efforts; to patients. and a enrollment long billion benefits we believe announce bring with this we can Where our significant pipeline I'm excited X XXX X completed Turning ASPEN have runway global in we our therapeutic that cervical DAXI randomized $X.X segment. phase

As DAXI ASPEN based inform FDA, doses international movement muscle potential DAXI approval package the cervical performs will a for in to study how center dystonia. on disorders. the you at data in registerational basis is comparing with discussions form Further, This larger program the XX will of placebo. our recall ASPEN the

track of to be XXXX. previously Enrollment in in results of and half should trial top on the second to that second half the announce As end II guided phase expected out expect before fasciitis Topline year. the results trial our is for also we of that completed XXXX. read the planter trial is from line in

spasticity, Turning the to of first of II half in with the of first should enrollment topline upper and results trial XXXX in phase XXXX. in continues half readout JUNIPER our the be limb complete

for continue studies glabellar accomplished in completing be aggregate, in pursuing. very enrolling X this therapeutics team lines, opportunity and two the and completing We we working therapeutics potentially the segment aesthetics are initiating and ASPEN regulatory, and first to been excited BLA. enrollment compile the R&D the of of the initial truly about a is quality, last studies in them, incredible all for fully can DAXI Xphase size. in position dystonia, XX teams DAXI indications This a X ever phase clinical the in trial cervical momentous feat phase X the In company in the our has our an SAKURA submission believe achievement manufacturing leadership months, four the achieve the with for

our covers corporate highlights. That recent

me call today's I'll over third Toby? to turn the closing begin let before our session. Q&A to Afterwards, summarize quarter Toby Now comments we few have financial a results.

Tobin Schilke

milestone decision from with This Botox. the move biosimilar to with ended the the figure we equivalents Starting Mark. spend quarter from with we by million for to through they limited a development expect payment license a XXXX of under have and quarter million. forward fourth program agreement investment April XXXX Mylan anticipate and collaboration a Mylan balance $X We you, $XXX that our third does with address In on cash the extend in our not their and decided to include will short-term cash, meantime, Thank payment activities. XX, proceed. decision whether to pre-IND of the

collaboration. Mylan collaborations will quarters Revenue and XXXX and respectively. as fluctuate for the of on make biosimilar development $XX,XXX Revenue the from in of consisted the Fosun third DAXI from we the progress quarter the the recognized Mylan coming

quarter so through the call. it million, stock-based full, we was in won't $XX.X The details I go issued our $XX.X Our the outlines and on was OpEx financial compensation, and results release depreciation excluding earnings million. today this during

Revance As the compensation expense in our of XXXX range million have in million excludes $XXX to of depreciation XXXX we to the million. be we range which in operating operating GAAP be stock-based guidance. expects and $XXX million $XXX $XXX to in expense, no the change to non-GAAP release, and said our

continue profile to thoughtful and and to through extend anticipated monitor manner. runway cash in our funding a of our XXXX expect We DAXI prudent approval lines. Currently, the we glabellar and

of Finally, October million basis. as XXXX Revance's or outstanding shares on million $XX.X fully approximately a $XX XX, diluted were

the back turn Mark. call to With I will that

Mark Foley

Thank you, Toby.

away weeks glabellar indication. lines are the for the from We BLA DAXI submitting

enters in half and year rich this catalyst corporate will launch second Following culminate and a that DAXI believe Revance events clinical of XXXX. meaningful of the submission, in approval the we of calendar

aesthetics the DAXI truly unlock approval optimize I continuing in to advance term longer therapeutic our busy We which also first ourselves neuromodulator, to are category writing programs forward look following while value. introducing created. the to since launch order novel to

With that for will now up I call questions. Operator? the open

Operator

comes Instructions] Our the of line question Samimy first [Operator Annabel Stifel. with from

line Your open. now is

Annabel Samimy

question. for taking my thanks Hi,

from prospective, a my I move role. questions. this fair it's of going I first time sitting a follow now And home. an at congratulations plans guess question, to envisioned to I right back strategic first perspective More now? over you into different strategic from well Mark you So looking that specific position or would say. you're there from few your I'm a all any ask this Are then on guess specifically evolve operating initiatives it's up commercial might as And maybe have

Mark Foley

the of I've of level. the first board for and two Well broader a sort years. been half at this hits on last

very decisions some obviously and So familiar strategy were the key of made. I'm with the that

deeper delivering a share continue in neuromodulator know We any I on make significant sure we would team, market is, to that We spend and I what got know to rationalize to we're while also we in therapeutic on into the strategy. focus going to and doing. that do just were for certainly spend a value which to value coming the the want can things which focus in on We you have meaningful question change successful recognize time focusing it that need expect do time were take capital the the the into therapeutic unlock on making time. to that continuing launch my all want that Having meaningful research space. But and to this in do So point has allocation. sure material we we our more not said over aesthetics in role on. get platform that with we the long-acting need at

launch of to enter want DAXI about the looking through going in aesthetics For at of market we additional that in the market. some question we middle research, your are the ways the market, different

time. in making necessarily have point great So incremental we're but progress at don't I to that on anything this

Annabel Samimy

why therapeutic just the so minute. I don't move for Okay, on a indications

wants given and the FDA broaden well see performed toxin So how disorders DAXI movement in general movement is toxin well label clearly there. disorders to and a of activity known pretty

more I question that studies, the you after moment guess detours to each to order going have belt is be with and get of going I DAXI's what clearly discipline path but much as facilitate going couple come your that you registrational areas? comfortable studies toxin So additional chances utilities in are studying it's may they sound the the great those not performance a be under are have CD mentioned moment the for that to is

Mark Foley

agency hard good to in this leading indication that a going is look speculate be to our first submissions the It's going CD were question; therapeutic at how subsequent following one. obviously after. will It's

continue the agency and more with to to structure have the work data information. probably appropriate closely we the will We as

focus right any the don't let's trials got So have charting I insight of forward we endpoints getting unique right a there. it's path that there, and know from then kind

Annabel Samimy

reading what Okay have and trial was to CD after that next Sorry next? missed of that? you I out was beyond the expect what the sort

Mark Foley

We [indiscernible] have. we spasticity we those are and that upper next got got two, the will readouts two limb

Annabel Samimy

Okay, thank alright you great, very much.

Mark Foley

You're welcome.

Operator

Thank you.

Piper Amsellem Our next the with of David line Jaffray. from comes question

Your is now open. line

David Amsellem

their want launching neuromodulator and philosophically I you to kind of views predecessor apologize and just of I having in a reported premium this, this couple priced pricing get actually Mark this morning. as results referred how whole your with your a look will landscape to and its product Just covered recently involve forth being. or this if premium has idea product experience but

landscape idea the So this experience is this about how Thanks. there is of and any philosophically your in feel competitive how that? product supportable predecessor you of premium a question on think between you that you philosophically is do got kind and daylight

Mark Foley

Great, question.

first really of I is of of first you of think other short can acting. think with I in launch into be I DAXI lump perspective, a So sort benefit the the market off, category going the neurotoxins a the all think to duration from

will into this I will be differentiated So marketplace. it innovation think bringing be the were new,

our and seen So what in excitement to even I of the generate we've kind be ability think than past. that do interest greater will

the pressure As right and about and more positioning over time. on think now we the only that's if premiums but going propositions, material into coming are differentiated and market aesthetics pricing category value and in innovation not environment market, today's the market, acting price were think short look other at markets, inevitably in to put I more command neurotoxins you the in

a consumers in marketplace However, to I are look think, premium I a outcome. to product, for with premium value command willing pay you a can that think certainly the and premium

for get premium providing rewarded outcome well. as will physicians I think a more

results difference bit short the of and I acting then there in market happening we of patients be in or extent the what think we've will more and decoupling to market will there, commands that space acting see trial but think a more broad good because price. remain and terms drives number the large longer through reproducible typical the command deliver in we work a follow for in stopped done curve we of the base that industry be I innovation the we can the little that innovation the the will what So it that value and

as very it sort I versus differentiated today. stand we're at stands market again of to looking think the out So offering product going a a

David Amsellem

by Or where this you the Okay in helpful a you going are about development programs further a you is you're your and are I therapeutic driven question worthwhile world not as here do way again on think programs? therapeutic therapeutic in the is look perfect and Revance that at the put program think the data, areas focusing and would that's exploration? another concerned various question realize to but decisions -- be of right that things that for terms on there be

Mark Foley

drive a duration today you at with and that benefit care very market, into back to data you the do, product that system terms where if a We cost with go fairly efficiencies. as obviously is look I the the a today and know, now $X.X based you in are I if lot of more side, market that differentiated how significant those on that existing it it's certainly in a a stands healthcare mature market. suggest market in categories already coming a product globally the think therapeutic the therapeutics It's go delivered. treatments For fewer sense. billion very got I We fact with makes to underpenetrated aesthetic straightforward the of meaningful lot know by markets in this product therapeutic mean

are those the so into. to And most go ones logical

good our information product works the at really us muscle are you disorders. those give trials think insight if that and movement look embarked in so already that And upon. to We we into

very as market know you side. category therapeutic and a single in the remains large biggest the migraine Obviously

about So over value we have how rationally to we time. think unlock

today, outside In terms treatment is [indiscernible] terms other sort current yet market which move that of to of of areas a see obviously category any toxins in gone but we fall into neuromodulators areas. that's of that indications into

what with a we product. will now category I better think think focus existing the we primarily on right is

David Amsellem

back the for Thanks insight and jump I in the will queue.

Operator

Thank you.

Our the Jacob of with from next Wells comes question Hughes line Fargo.

open. now is line Your

Jacob Hughes

options that? you think not what obtain can share Good questions, years? the you for Mylan next are few for comment afternoon. your if the secondly, kind company two I capture on biosimilar what the to just program have chooses could And over of

Mark Foley

their would some Sure, premature drive going what is today. founded commercialization that so thus We from related consumers. on of we've think the and at both that and and look our make decision-making could I somewhat terms consumers you necessarily indicate on done improvement take, think to long-acting important physicians it's that kind based most of over neuromodulator to research the neuromodulator the and share work market share work of it our going far we're footprint. XX% with we've in to strategy Certainly, of that's launch

a in it's execution I sort product share of market. of with do on hard your Then think we So meaningful and to but that very that right question side was could be shares commercial say Mylan the differentiated takers it. second the

we parties time. If program, like you of interest number step other time when had that best that a partner the at we back, that whole started was this Mylan that the we felt expressed

bit Mylan of their and little us program, some We that of $X they a going obviously paid continue that another that to for the things looks because on to advance decision delay internal they million.

get figure terms continue whether end in and them to are we of forward we So in opt or path. pursue based April move obviously on or we clarity we not that an of the to will decision alternative whether by going they with then whether will

Jacob Hughes

new you and congrats thank on a Okay role.

Mark Foley

appreciate you, it. Thank

Operator

Thank you.

the from line comes question Company. next Ku Cowen of Stacy & Our with

now is line Your open.

Stacy Ku

Hi, all have questions. few. progress. my on Congratulations for I thank the you taking a

you And one more thinking thing questions? we as spend approach have be to XXXX. how can about should remind next As year, two us I operating in you

Mark Foley

in We be details the terms give the we of get will our side certainly of haven't through able spend on spend this you given of XXXX as to more clarity color it.

Stacy Ku

file you in can commercial also on might with timelines internationally, and discussions? DAXI U.S timing with this fair partner to how comment That's cogs

Mark Foley

I'm to to that question, it turn over that. That's on a comment going good for Abhay to

Abhay Joshi

the file first. for international US doing six initially be plans or and international months after be start with would starting filings we to EU US filing for market our talked and goal we so the that about you months after files as six that So would about

Stacy Ku

prior be Mylan XXXX remind program, the and April we enabling your updates to studies? expecting us financial Mylan's incremental Finally contribution to any can of should you IND regrind

Mark Foley

so million any are $XX million regulate more $XX and with prior other add us make going the and bit and some there don't give to to that, that's contributed expect that I the to and clarity timing Toby end to but Mylan upfront for opt stated Mylan Today incremental April this. but payments dictate less, prior would chose $X million associated to would to out, milestone be this, little payments a that an we really decision of a reason, on whatever too. in and

Tobin Schilke

looking lead we to at you Mylan? purposes, on or spend you're how recognize for can If revenue look modeling

Stacy Ku

Alright, thank you so much.

Operator

Thank you.

comes Wainwright. question H.C. line next of Our Tsao from with the Douglas

Your line is open.

Douglas Tsao

Hi, questions. good afternoon thanks of terms couple Mark taking a the in for development.

use Just curious data plan around for you and or sufficient the for their headlines those X the get of Crow's phase phase would on drive, in as on phase X, especially and technique have dosing would do physicians and we then you conducting own? it terms the feet, think on X to study to or be

Mark Foley

great or necessarily advantages Its we're the have but has there aesthetics single indications will those. sort to advancing to duration that on product in and think only that look decide data of the of the mean indication, And release that I clearly will they will full not efficacy in facial have data now there's player side time indication commercialize question, into at we But readouts one the phase be it. planning single have X. that whether we I X phase at wait market, a with that We continue of beyond see, their data. we think the won't for right sort today's and a

Douglas Tsao

in with give therapeutic, then you terms Okay the is of in update company of great. maybe terms migraine? And an where could

Mark Foley

programs look and the we think would the on already potentially initiate said therapeutic update. I to program. rolling reported are we for in previously that, that we other provided in trials what migraine Obviously, XXXX is

team, allocation going senior So that's to are we that. one capital to look were to through around that continuing continue go as strategy a and the decisions

the migraine. certainly we So of recognize importance

when any it's give position this at time to that. a if, it's and clarity question of So to willing on I'm me just not more an not to

Douglas Tsao

Okay, you Thank enough. fair very much.

Operator

you. Thank

Lugo with the question of from William next Our line Tim Blair. comes

line is now open. Your

Tim Lugo

what on differentiated to for taking DAXI Thanks obviously a transition. smooth is product. from Maybe higher a question seems my like and congratulations with view market coming

However, bundle own. product, you do it obviously from larger view transition would still suite against of against you a the some products competitor competing its also having is that how competitor be that and and is your marketing currently of just only larger one

So if that sales maybe could the about from hearing transition or can you're for you from force that talk anything anything which disturbances beneficial be launched?

Mark Foley

mean question. great it's I

seen because in certainly that a and aesthetics think successful launch that they in I without a patient product have competitive a think to physician physicians have neuromodulator been other and trying the certainly in will to bundle with product. differentiated products able is unique commercial we have so in choices with any certainly possible other and entrance it's products interested bundle, interest alternative in so recent the I successfully that think generate that we the I single

will feel So that of products the question, we mindful continue that. said right successful to pretty be way were and more the proposition. can other efficiencies, we position create think compelling sorry. think be to to the our of good continue we now are we contribute our along there that for value able don't to market look in create of how then things the other it. we And success, But that if to believe because at your Having about party consumer, we will I the I'm course offer either launch need

Tim Lugo

or your occurring could could that large potentially disturbances product anything acquisition salesforce that about anything launch? hearing you competitors your Are during from own be benefit

Mark Foley

Not necessarily.

and and capturing now that large think market of the meaningful it's as players well so market as gives know needs. there, an certainly It that but really of a are touch the will sort of you the and look single are product opportunity you on in that structured it at is some them all we going changes customer think the that, a and to people focus was changing to I some kind business or margin. much organizations serve the way that both undergoing any acquisition us if undergoing I business are of right efficiencies in high in be the very there's try be usual aesthetics those two that

Tim Lugo

thanks Understood, for questions. the

Operator

you. Thank

comes with Our Yang next Difei Mizuho line from question of Securities. the

now is line Your open.

Difei Yang

for Good afternoon question, few taking just and thanks my a here.

the millennial where longer The a [ph] will accepted major How market, will you effecting neuro-aesthetics to market. you the the play think given role spending play to millennial by first are be acting who market? one in do future new relate DAXI will important

Mark Foley

It's this that question. good a We we got a done lot research of market category. in different

reality I still so market segments. under is this think, I resonates underpenetrated all neurotoxin along think the is across acting

valuable know don't this long-acting to I So say or that going to at fair of segment more given it's not. sort segment to look be is any on

I just think across it's strong we with of and have longer would there the correction certainly as to certainly younger that seeing office going like would And a people earlier well the all just at millennial to work full that allows or segments. done we've the it think the resonate in neuromodulator engagement physician's aesthetic twice-a-year. I that acting appeal are because it have coming a procedures to in somebody

Difei Yang

you Thank which than sort a label do you label that's European wrinkle of than competitors acting How days that? the three, do approval recently, assured of is longer received so is your their then of of typically, neurotoxin most months and longer four our which typical with XXX with kind label. one

Mark Foley

across very I compelling wide benefit that consistent very and on the running neurotoxin variety a that just our extent the is on to of we're our demonstrate robust has duration. so trials focused to of clinical data think really neurotoxin Well, groups

fact that Certainly, if think to show of reflected in randomized data of at certainly looking that for the trials benefit be research label. data point of reason I are that's in look and the be. to I if so to any product to different we you were are stabilizing reasons were And running the think that having speak these to that to standard peptide PRS. a me markets, terms by the that a of might it's the data and of duration in agencies can we why the really evidenced its type be and acceptance because you the that think our open need you feel in at that going SAKURA that was gold these they needed in our going important clinical to

the caliber that clinical that trials that's in going demonstrating important that think running think be we ultimately terms I to and we're reflects of really the of duration.

Difei Yang

you. Then any from is on Thank my final question China? updates

Mark Foley

real might recall with there, from as updates that No we them. deal structured you the

going are IT, define to clinical and on the requirements so get and commercial are all clinical working the through end are do going the onto still the We work they their holding all still through, they and to in trial be trial were to workings what to process approval that marketplace.

Difei Yang

Thank taking questions. my you for

Operator

you. Thank

comes Belanger Needham. with from Serge the question of Our next line

now line Your is open.

Serge Belanger

be you mentioned you what just you be Can tell this positions point? remarks there some sizing Mark, and thinking additional the me. whether in for the questions higher that side. at filled of key made prepared on key couple salesforce afternoon, commercial we about need to Good us should

Mark Foley

think the well. that at the from, in now. We right we think sales of these that we're where just where we hired if people and space they in very it's very market the leading you got experienced and look right senior in players the aesthetic caliber from on coming marketplace at of so Yes, leadership of know and the are pedigree the believe the people ahead come the I I

data place senior the now our market I we we so leadership got think right commercial the inform right go to side in team to And on and believe market the right we research all strategy. got

going as able to information that probably and more high number further just launch give number of as haven't given we what but refine it along get we which to level tailor will terms planning we we the articulated the reps. doing of we I competitive our that time be reasons, we're but clarity be terms a in were strategy have In sales a salespeople the of to little the side on won't yet and until invest really sharing probably bit commercial think we terms a frankly, in be planned for and operating spend yet,

Serge Belanger

asked business And I front, complement any in if think aesthetic then x-US appetite you also products development additional licensing about, to been DAXI? rights an out but license you on is commercial there

Mark Foley

will strategy the best the rights other continue that licensing as in is who path of something close we look partner relationship down by these out Certainly to on markets in we the for evidenced the that is x-US an we continue have.

DAXI additional that products that's it successfully we or any to than product more provide would products delude that own. As look those we consumer bring we on successful successful a don't be with can practice things. would and launch; to we can the not absolutely have part think said need at But be the now, that stands I mentioned as think we value to and launch our are efforts so the that, value strategy. feel DAXI would we a aesthetic its alone successful that right we necessary of our can there feel Having earlier, that

Serge Belanger

you. Thank

Mark Foley

Great, thank you.

Operator

you. Thank

Fernandez Our the of comes Guggenheim. line from next question of Seamus

now is open. line Your

Seamus Fernandez

thanks Great, question. the for

us of to us is type the and outlicensing understand be then the break the that in profile Botox from question target in second meaningful the your would can cervical help the the product European fact you comparator second actually trial. product type believe of could it and a XXXX. understand timeline, to forward out your today a help choosing but most So duration perspective you there in European necessary dystonia that doesn't and just therapeutics regulators if I would head-to-head us is required. where Mark. that a in treatment half Can clinically require that likely just comparator again, the of as would market, What getting CD? couple treatment be seem perhaps be And look is maybe be in market. And typical specifically on we in given like a you aesthetics, profile of terms asset data what would

Thanks. and how in just partners think the the type choice products So of you guys of wondering situation. about that competitor would

Mark Foley

Great questions.

to one relates Abhay the the question to So from meaningful sort to second we take comparator will of turn there. I'm what's and CD going over then

Abhay Joshi

think the trial designed. of Seamus, about how and CD launching was part CD how the first we question about was

compared go that phase the did we where strongly or longer you on compared that chose approved [indiscernible] twister comparing DAXI to based in as end If we points XX weeks performed with II duration to very as have score. the clinical back to trial program of the market superb the the chose. showed endpoint or products for you other we

know that launched our had go And we phase to after based confident you data to and the So program trials all that. we the tremendous III agency. as directly on

And twister designed similar which specify two phase what neuromodulars So this III primary Toronto then score is and other our indeed impact X for we of to to where that II the components data. that have twister what end duration going our phase on show based is actively again trial our it, a secondary is X program endpoint on primary weeks done. and before for based is X consistent scale with of the phase from the and average change twister program X back a at study are the phase our points in endpoint to an done baseline have

see to profile. similar expect We

Mark Foley

in duration between and the marketplace? on comment your typically Then what seeing the what's are we difference

Abhay Joshi

take of have out and Then based I are there three think equation, if different there points which out products you couple been different end the twister of on approved scales. the then

weeks but the optimal label XX weeks. to a So actually is product start XX around the off varying about generally who a XX weeks is X seeing XX to level for cervical dystonia to XX label the and patient

to in up for XXX we in way X weeks. study have phase all all different shown doses DAXI, we of million all that to taken DAXI at compare where You units the open categories least the the escalating data effect, our [indiscernible] XX duration have the was product that label

you approved within duration can the of X much delta DAXI. for comparing So currently vis-à-vis XX in XX two weeks almost market, to that's imagine times weeks product the as the

Mark Foley

we've with at healthcare meaningful Before the market to look answer say taking based it's research next the on design therapeutic the sort area will cost if at and share trial longer in and you we profile and involved and of duration done about everything, that look Europe I what's there. the question extensive

to also it second Abhay the relates to aesthetic XX XX X enough difference on weeks side provides maybe And of it the to we was over as sort of out one trials versus think and drive value in Abhay turn any existing meaningful that pointed weeks, products therapeutic. So, there's this the today and share EU think about and the to endpoints whether label capture. between

Abhay Joshi

to data testimony a we EU you on Europe in for aesthetics for know therapeutics In we trial it's stand to think answer our the regards filing as have that our in here, you wish U.S. I going simple its don't some in pretty trials the decide the the place a forward. would the I acquired mentioned current global depending based upon Mark of have yet, because work you was have that that you trying your with as to partner competitor we're right be who will and I but trial work who answer for collaborative better market So

So I at this say point tuned. would stay

Seamus Fernandez

I If quick one would reasonable have prospect a question great the just the partners. Europe in follow that, bit that come carving that can dynamic, to play thanks opportunity ask pricing so I up? of pricing separate be therapeutic I of a don't with into up follow-up aesthetic consider sense into it is for would and how know can just

Mark Foley

over to one. that I hit to will it Dustin hand

Dustin Sjuts

and at upon aesthetic there. they [Technical it that, at I the but that part part Difficulty] make the look we to as best look able think therapeutics think of and I valuation best are do we of

Mark Foley

we we or whether we obviously just to a we both that's [indiscernible] an divide certainly find mindful of that pricing up, us. whether sort them do the we be need we things can feel split feel would them but of single side for So option

Seamus Fernandez

very Thanks much.

Operator

Thank any to the would closing I'm for to showing now call at Foley this time. not like over I you. remarks. turn Mark questions further

Mark Foley

Revance in of face-to-face many to excited you forward role meeting with I'm operator. with I'm new looking and you, about Thank my the coming months.

schedule, In Please shows Stifel Francisco, reach conferences. term and will we Suisse, be Piper Jeanie to York plus terms Boston in attending of out Guggenheim, investor if the health care conducting near and San our credit road travel New you're today's thank or call. that, if in you area call. you you all when With great I for day. to schedule participating our us the like a to of Have rest would like to in a meet like with

Operator

conference. for and this you gentlemen, Ladies today's participating. Thank concludes

You day. may Everyone, disconnect. a now wonderful have

Revance Therapeutics (RVNC) 4 Nov 192019 Q3 Earnings call transcript